<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300235</url>
  </required_header>
  <id_info>
    <org_study_id>1319</org_study_id>
    <secondary_id>U54HL070587</secondary_id>
    <nct_id>NCT00300235</nct_id>
  </id_info>
  <brief_title>Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence</brief_title>
  <official_title>The Epidemiology of Priapism (Sickle Cell Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Priapism, a prolonged erection of the penis, is a medical issue that often affects men with
      sickle cell disease. The purpose of this study is to collect demographic and clinical
      information on priapism by interviewing men with sickle cell disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Priapism is a prolonged, painful erection of the penis that lasts for more than four hours
      and occurs without sexual stimulation. It occurs when blood in the penis becomes trapped and
      is unable to drain properly. If it is not treated immediately, it can lead to scarring and
      permanent erectile dysfunction. Many cases of priapism are the result of sickle cell disease;
      approximately 42% of all adults with sickle cell disease will eventually develop priapism.
      Current treatments include medication, ice packs, or surgery. More research is needed to
      better understand the demographic and clinical characteristics of priapism. The purpose of
      this study is to collect information and further characterize priapism by conducting
      interviews with men with sickle cell disease. In turn, these findings may guide future
      priapism clinical trials.

      This study will consist of two standardized questionnaires that will be administered to 1,650
      men with sickle cell disease. Participants will complete an initial five-item questionnaire
      about priapism. If a participant indicates past experience with priapism on this initial
      questionnaire, he will be asked to complete a second questionnaire. This questionnaire will
      ask in-depth questions to further characterize the participant's episodes of priapism. If
      health issues such as drug use, harmful sexual behaviors, or impotence are identified upon
      reviewing the questionnaire, clinic staff will suggest care options and provide appropriate
      referrals to the participants. All participants will receive an educational brochure about
      priapism and compensation for completing the questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Enumeration of the Prevalence of Priapism in Males With Sickle Cell Anemia and Sickle Beta Zero Thalassemia.</measure>
    <time_frame>At time of interview</time_frame>
    <description>Subject responded YES to survey Question &quot;Have you ever had priapism?&quot;. By diagnosis and age group. Enumeration of the prevalence of priapism in males with sickle cell anemia and sickle beta zero thalassemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of Priapism in Males With Sickle Cell Anemia With Reference to Time of Onset, Duration of Events, Frequency of Episodes, Precipitating or Associated Activities, Treatment Modalities Used, and Outcome of Treatments</measure>
    <time_frame>Cross-sectional single survey visit</time_frame>
    <description>Characterization of priapism in males with sickle cell anemia with reference to time of onset, duration of events, frequency of episodes, precipitating or associated activities, treatment modalities used, and outcome of treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive Comparison of the Prevalence of Priapism in Males With Sickle Cell Anemia to That Described in Older Patients With Other Sickle Hemoglobinopathies</measure>
    <time_frame>Cross-sectional single survey visit</time_frame>
    <description>Descriptive comparison of the prevalence of priapism in males with sickle cell anemia to that described in older patients with other sickle hemoglobinopathies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of General Patient and Parent Understanding of Priapism as a Complication of Sickle Cell Disease Gained From Completion of Protocol</measure>
    <time_frame>Cross-sectional single survey visit</time_frame>
    <description>Assessment of general patient and parent understanding of priapism as a complication of sickle cell disease gained from completion of protocol.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">1464</enrollment>
  <condition>Priapism</condition>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>200 subjects ages 5 to 9.9 years with a diagnosis of HbSS/HbSβ0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>400 subjects ages 10 to 14.9 years with a diagnosis of HbSS/HbSβ0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>400 subjects ages 15 to 24.9 years with a diagnosis of HbSS/HbSβ0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>400 subjects over the age of 25 with a diagnosis of HbSS/HbSβ0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <description>250 subjects age 15 and older with a diagnosis of HbSC or HbSβ+</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Males receiving care in any Comprehensive Sickle Cell Center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of sickle cell anemia or sickle beta zero thalassemia, if 5 years of age or
             over OR

          -  Diagnosis of sickle beta plus thalassemia or sickle hemoglobin C disease, if 15 years
             of age or over

          -  Participant and/or parent or guardian must be able to communicate adequately with the
             interviewer

          -  May participate if currently taking hydroxyurea, undergoing chronic transfusion, or
             participating in other research studies, including those involving treatments such as
             arginine, if all other inclusion criteria are met

        Exclusion Criteria

        Subjects who meet any of the following criteria are disqualified from enrollment in the
        study:

          1. Patient or parent/guardian declines participation.

          2. Female.

          3. Subject or parent/guardian unable to communicate adequately with the interviewer.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir Ballas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lennette Benjamin</last_name>
    <role>Study Chair</role>
    <affiliation>Montefiore Medical Center and Children's Hospital of Montefiore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Bessman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Southwestern at Galveston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Cain, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UT Children's Hospital of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lewis Hsu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Christopher's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura DeCastro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cage Johnson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California Los Angeles County &amp; University of Southern California Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Kalinyak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Lieff, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rho, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lillian McMahon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Mentzer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California San Francisco Pediatric Hematology/Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashok Raj, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norton Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rupa Redding-Lallinger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zora R. Rogers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Southwestern Medical Center at Dallas and Children's Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Rutherford, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas, Southwestern Medical Center at Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Smith-Whitley, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elliott Vichinsky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital and Research Center at Oakland &amp; Summit Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Winfred Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Snyder, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn Hassell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Heeney, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Kraut, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stacy Month, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kaiser Permanente - Oakland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maureen Okam, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Courtney Thornburg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center at Oakland &amp; Summit Medical Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente, Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610-0383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital at Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center and Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Parkland Health &amp; Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2006</study_first_submitted>
  <study_first_submitted_qc>March 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2006</study_first_posted>
  <results_first_submitted>March 13, 2009</results_first_submitted>
  <results_first_submitted_qc>June 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2009</results_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Zora R. Rogers</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Priapism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Age 5-9.9 HbSS/HbSβ0</title>
          <description>Subjects 5 to 9.9 yrs w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="P2">
          <title>Age 10-14.9 HbSS/HbSβ0</title>
          <description>Subjects 10 to 14.9 ys w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="P3">
          <title>Age 15-24.9 HbSS/HbSβ0</title>
          <description>Subjects 15 to 24.9 yrs w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="P4">
          <title>Age &gt;25 HbSS/HbSβ0</title>
          <description>Subjects &gt; 25 yrs w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="P5">
          <title>Age &gt;15 HbSC/HbSβ+</title>
          <description>Subjects &gt; 15 yrs w/SCD diagnosis HbSC/HbSβ+</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="240"/>
                <participants group_id="P3" count="398"/>
                <participants group_id="P4" count="362"/>
                <participants group_id="P5" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="240"/>
                <participants group_id="P3" count="398"/>
                <participants group_id="P4" count="362"/>
                <participants group_id="P5" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Age 5-9.9 HbSS/HbSβ0</title>
          <description>Subjects 5 to 9.9 yrs w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="B2">
          <title>Age 10-14.9 HbSS/HbSβ0</title>
          <description>Subjects 10 to 14.9 ys w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="B3">
          <title>Age 15-24.9 HbSS/HbSβ0</title>
          <description>Subjects 15 to 24.9 yrs w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="B4">
          <title>Age &gt;25 HbSS/HbSβ0</title>
          <description>Subjects &gt; 25 yrs w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="B5">
          <title>Age &gt;15 HbSC/HbSβ+</title>
          <description>Subjects &gt; 15 yrs w/SCD diagnosis HbSC/HbSβ+</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="208"/>
            <count group_id="B2" value="240"/>
            <count group_id="B3" value="398"/>
            <count group_id="B4" value="362"/>
            <count group_id="B5" value="251"/>
            <count group_id="B6" value="1459"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="84"/>
                    <measurement group_id="B6" value="735.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="361"/>
                    <measurement group_id="B5" value="165"/>
                    <measurement group_id="B6" value="721.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" spread="1.44"/>
                    <measurement group_id="B2" value="12.6" spread="1.46"/>
                    <measurement group_id="B3" value="19.3" spread="2.72"/>
                    <measurement group_id="B4" value="36.0" spread="8.93"/>
                    <measurement group_id="B5" value="29.8" spread="13.69"/>
                    <measurement group_id="B6" value="22.5" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="398"/>
                    <measurement group_id="B4" value="362"/>
                    <measurement group_id="B5" value="251"/>
                    <measurement group_id="B6" value="1459.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="398"/>
                    <measurement group_id="B4" value="362"/>
                    <measurement group_id="B5" value="251"/>
                    <measurement group_id="B6" value="1459.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Enumeration of the Prevalence of Priapism in Males With Sickle Cell Anemia and Sickle Beta Zero Thalassemia.</title>
        <description>Subject responded YES to survey Question &quot;Have you ever had priapism?&quot;. By diagnosis and age group. Enumeration of the prevalence of priapism in males with sickle cell anemia and sickle beta zero thalassemia.</description>
        <time_frame>At time of interview</time_frame>
        <population>All particpants who completed survey were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 5-9.9 HbSS/HbSβ0</title>
            <description>Subjects 5 to 9.9 yrs w/SCD diagnosis HbSS/HbSβ0</description>
          </group>
          <group group_id="O2">
            <title>Age 10-14.9 HbSS/HbSβ0</title>
            <description>Subjects 10 to 14.9 ys w/SCD diagnosis HbSS/HbSβ0</description>
          </group>
          <group group_id="O3">
            <title>Age 15-24.9 HbSS/HbSβ0</title>
            <description>Subjects 15 to 24.9 yrs w/SCD diagnosis HbSS/HbSβ0</description>
          </group>
          <group group_id="O4">
            <title>Age &gt;25 HbSS/HbSβ0</title>
            <description>Subjects &gt; 25 yrs w/SCD diagnosis HbSS/HbSβ0</description>
          </group>
          <group group_id="O5">
            <title>Age &gt;15 HbSC/HbSβ+</title>
            <description>Subjects &gt; 15 yrs w/SCD diagnosis HbSC/HbSβ+</description>
          </group>
        </group_list>
        <measure>
          <title>Enumeration of the Prevalence of Priapism in Males With Sickle Cell Anemia and Sickle Beta Zero Thalassemia.</title>
          <description>Subject responded YES to survey Question &quot;Have you ever had priapism?&quot;. By diagnosis and age group. Enumeration of the prevalence of priapism in males with sickle cell anemia and sickle beta zero thalassemia.</description>
          <population>All particpants who completed survey were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="398"/>
                <count group_id="O4" value="362"/>
                <count group_id="O5" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="160"/>
                    <measurement group_id="O4" value="189"/>
                    <measurement group_id="O5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This was a survey designed to estimate prevalence, no formal comparisons between age or genotype groups were performed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>proportion of subjects</param_type>
            <param_value>35.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>32.5</ci_lower_limit>
            <ci_upper_limit>37.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization of Priapism in Males With Sickle Cell Anemia With Reference to Time of Onset, Duration of Events, Frequency of Episodes, Precipitating or Associated Activities, Treatment Modalities Used, and Outcome of Treatments</title>
        <description>Characterization of priapism in males with sickle cell anemia with reference to time of onset, duration of events, frequency of episodes, precipitating or associated activities, treatment modalities used, and outcome of treatments.</description>
        <time_frame>Cross-sectional single survey visit</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Descriptive Comparison of the Prevalence of Priapism in Males With Sickle Cell Anemia to That Described in Older Patients With Other Sickle Hemoglobinopathies</title>
        <description>Descriptive comparison of the prevalence of priapism in males with sickle cell anemia to that described in older patients with other sickle hemoglobinopathies.</description>
        <time_frame>Cross-sectional single survey visit</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of General Patient and Parent Understanding of Priapism as a Complication of Sickle Cell Disease Gained From Completion of Protocol</title>
        <description>Assessment of general patient and parent understanding of priapism as a complication of sickle cell disease gained from completion of protocol.</description>
        <time_frame>Cross-sectional single survey visit</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Age 5-9.9 HbSS/HbSβ0</title>
          <description>Subjects 5 to 9.9 yrs w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="E2">
          <title>Age 10-14.9 HbSS/HbSβ0</title>
          <description>Subjects 10 to 14.9 ys w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="E3">
          <title>Age 15-24.9 HbSS/HbSβ0</title>
          <description>Subjects 15 to 24.9 yrs w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="E4">
          <title>Age &gt;25 HbSS/HbSβ0</title>
          <description>Subjects &gt; 25 yrs w/SCD diagnosis HbSS/HbSβ0</description>
        </group>
        <group group_id="E5">
          <title>Age &gt;15 HbSC/HbSβ+</title>
          <description>Subjects &gt; 15 yrs w/SCD diagnosis HbSC/HbSβ+</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="398"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="362"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="251"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Kesler, PhD</name_or_title>
      <organization>Rho Federal Systems Division</organization>
      <phone>919-408-8000 ext 244</phone>
      <email>karen_kesler@rhoworld.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

